Updates are available Correction dated 2025-05-01
Click to view Correction: https://doi.org/10.1038/s41598-025-95009-7
-
Authors
Ludolph, Albert C.
Grandjean, Harish
Reviers, Evy https://orcid.org/0000-0002-6044-5234
De Micheli, Valentina
Bianchi, Cosetta
Cardosi, Leonardo
Russ, Hermann https://orcid.org/0000-0002-4346-4214
Silani, Vincenzo https://orcid.org/0000-0002-7698-3854
- License Information
-
More Information
Article History
Received: 16 March 2023
Accepted: 7 December 2023
First Online: 15 December 2023
Change Date: 1 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-95009-7
Competing interests
: The patient preference survey was sponsored by Zambon Biotech S.A. Data collection and analysis were carried out by Charles River Associates International (CRA), Switzerland, and funded by Zambon Biotech. Article processing charges were funded by CRA. Zambon Biotech S.A. has contracted CRA to conduct the Patient Preference Survey. V. Silani, and A. Ludolph have received personal fees from CRA for this research, including contributions to the development of the survey and review of the data. A. Ludolph is supported by the Deutsche Forschungsgemeinschaft, the Bundesministerium für Bildung und Forschung (BMBF), the European Union (HORIZON), the State of Baden-Württemberg, the Deutscher Akademischer Austauschdienst (DAAD) and receives funds for clinical trials and consulting services (advisory boards, speaking activities) from IONIS, Biogen, Novartis, AveXis, Cytokinetics, Italfarmaco, Teva, Zambon Biotech S.A. and Amylyx. H. Grandjean is an employee of CRA. E. Reviers have no relevant financial or non-financial interests to disclose. V. De Micheli is a employee of Business Integration Partners S.p.A. Life Sciences Division and a consultant for Zambon Biotech SA. C. Bianchi is a consultant for Business Integration Partners S.p.A. Life Sciences Division and a consultant for Zambon Biotech SA. L. Cardosi was an employee of Zambon SPA at the time of the realization of the manuscript. H. Russ is a Sirius Scientific Consulting employee and a medical consultant for Zambon. V. Silani has received personal fees from Zambon Biotech S.A. for activities outside the submitted work. V. Silani received compensation also for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., and Novartis Pharma AG. He receives or has received research supports from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is on the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology, and Exploration of Neuroprotective Therapy.
